CGON CG Oncology, Inc. Common stock
Healthcare$61.89-3.67%ClosedMarket Cap: $5.46B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.97
P/S
1117.53
EV/EBITDA
-28.49
DCF Value
$-2.88
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-47.0%
Operating Margin
-4239.0%
Net Margin
-3682.6%
ROE
-23.3%
ROA
-16.4%
ROIC
-19.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.1M | -173.5% | $-66.4M | $-60.2M | $— | — |
| Q4 null | $2.3M | -25.5% | $-48.7M | $-41.3M | $— | — |
| FY null | $4.0M | -15.0% | $-190.8M | $-161.0M | $— | — |
| Q3 null | $1.7M | 5.3% | $-51.1M | $-43.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-48.7M | $-41.4M | $— | — |
| Q1 null | $52.0K | 100.0% | $-42.2M | $-34.5M | $— | — |
| Q4 null | $456.0K | 100.0% | $-38.0M | $-31.8M | $— | — |
| FY null | $1.1M | 100.0% | $-114.7M | $-88.0M | $— | — |
| Q3 null | $43.0K | 100.0% | $-28.3M | $-20.4M | $— | — |
| Q2 null | $111.0K | 100.0% | $-25.9M | $-18.9M | $— | — |
| Q1 null | $529.0K | 99.2% | $-22.5M | $-16.9M | $— | — |
| Q4 2023 | $1.0K | -300.0% | $-18.9M | $-16.1M | $-0.33 | — |